The FDA's Breakthrough Device Designation (BDD) is a voluntary program that enables medical device developers to receive more efficient and effective development and review of certain devices. It was established by the 21st Century Cures Act (2016) and formalized in the FDA Reauthorization Act (2017).

Eligibility Criteria

A device is eligible for Breakthrough Device Designation if it:

  1. Provides for more effective treatment or diagnosis of a life-threatening or irreversibly debilitating disease or condition; AND
  2. Meets at least one of: (a) represents a breakthrough technology, (b) no approved alternatives exist, (c) offers significant advantages over approved alternatives, or (d) availability is in the best interest of patients.

Benefits of Designation

The Breakthrough Device Designation provides:

  • Priority review: Faster FDA review timelines for IDE applications and eventual marketing applications
  • Interactive review: Increased interactions with FDA during development — companies can meet with FDA more frequently to discuss study design and device requirements
  • Senior-level FDA engagement: Senior FDA staff involvement ensures consistency and expertise throughout the development program
  • Enrollment flexibility: More flexibility in clinical trial designs, including adaptive trials

Critically, BDD does not lower the evidentiary standard for approval — devices must still demonstrate safety and effectiveness. It accelerates the timeline by improving communication and reducing administrative delays.

BCI Devices with Breakthrough Designation

Several BCI devices have received FDA Breakthrough Device Designation:

  • Synchron Stentrode: Received BDD in August 2020 for severe motor paralysis (ALS, locked-in syndrome)
  • Precision Neuroscience Layer 7: Received BDD in 2023 for motor paralysis
  • ONWARD Medical ARC-EX: Received BDD for epidural stimulation in spinal cord injury

Comparison to Drug Breakthrough Designation

The Breakthrough Device Designation for devices is conceptually similar to the FDA's Breakthrough Therapy Designation for drugs, but administered by CDRH (Center for Devices and Radiological Health) rather than CDER (Center for Drug Evaluation and Research). Both designations aim to get potentially transformative therapies to patients faster while maintaining rigorous safety and effectiveness standards.